Anders Blanck – Director General, LIF, Sweden

Anders Blanck, director general of LIF, Sweden’s association representing the research-based pharmaceutical industry, breaks down the ins and outs of the country’s regionalized healthcare system and the drivers of the Swedish pharmaceutical market. He then delves into the reforms Sweden needs to undertake for its healthcare system to adapt to next-generation cell and gene therapies and regain its position as a testbed for innovative medicines.  
Over the past five years, drug expenditures per capita have actually declined, while overall healthcare expenses per capita have increased by 30 percent
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report